ArticleIndian journal of surgical oncology2025
Surgical Management of Solid Pseudopapillary Neoplasm of the Pancreas-an Experience from Tertiary Care Centre.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Management and outcomes of solid pseudopapillary neoplasm of the pancreas: a systematic review.Clinical and experimental medicine · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid pseudopapillary neoplasm (SPN) is uncommon and constitutes to 1-2% of pancreatic tumours. Owing to its rarity, literature is sparse on its clinicopathological characteristics and surgical outcomes. Our study is a retrospective analysis of prospectively maintained data of patients with histologically proven SPN between January 2012 and December 2019. Patients' demography, clinical presentation, preoperative imaging, operative details, perioperative outcomes, and long-term follow-up were recorded and analyzed. A total of 14 patients were included in the study, all were females with a median age of 19.5 years (range 15-35 years). All presented with pain abdomen. Eight (57.1%) out of 14 patients were correctly diagnosed with contrast-enhanced computed tomography (CECT) abdomen. CECT revealed solid cystic well-encapsulated lesions in 12(85.7%) and homogenous mass lesions without cystic changes in 2 (14.2%) patients. The most common tumour location was head/uncinate process (57.1%). Eight (57.1%) underwent pancreaticoduodenectomy and 6 (42.8%) had undergone distal pancreatectomy. The median size of tumour was 10 cm (4.5-14 cm). The median postoperative stay was 9 days (range 4-20 days). Seven patients (50%) developed postoperative pancreatic fistula (Grade-A-6/7, Grade-B-1/7) and delayed gastric emptying (DGE) was noted in two (14.2%). R0 resection could be achieved in 13 patients (92.8%). Median follow-up period was 49.5 months. One patient had postoperative recurrence after 48 months of surgery. SPN is a rare tumour of pancreas. Surgical resection is associated with acceptable morbidity and is required for potential cure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.